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Abstract
Background: Several different commercial one-cycle labeling kits are available for preparation of
the target for use with the Affymetrix GeneChip platform. However, there have been no
evaluations of these different kits to determine if comparable results were generated. We report
on the cRNA target synthesis, labeling efficiency and hybridization results using the One-Cycle
Target Labeling Assay™ (Affymetrix), the BioArray RNA Amplification and Labeling System™
(Enzo Life Sciences), and the Superscript RNA Amplification System (Invitrogen Life Technologies).
Results: The only notable difference between kits was in the yield of cRNA target synthesized
during in vitro transcription, where the BioArray assay had to be repeated several times in order
to have sufficient target. However, each kit resulted in comparable signal and detection calls when
hybridized to the Affymetrix GeneChip.
Conclusion:  These 3 one-cycle labeling kits produce comparable hybridization results. This
provides users with several kit options and flexibility when using the Affymetrix system.
Background
There are several commercially available one-cycle labe-
ling kits that generate targets for use with Affymetrix
GeneChip technology. Commercial labeling kits are valu-
able because they eliminate the need for individual labo-
ratories to optimize methods, saving both time and
resources. They also allow better cross-comparison of
results generated from different laboratories. However,
this assumes that all approaches produce comparable
labeled targets. Given the widespread use of several labe-
ling kits with the Affymetrix technology, we evaluated
cRNA target synthesis, labeling and hybridization results
using 3 different one-cycle linear amplification labeling
kits. These were the One-Cycle Target Labeling Assay from
Affymetrix (One-Cycle), the BioArray™ RNA Amplifica-
tion and Labeling System from Enzo Life Sciences (BioAr-
ray), and the Superscript™ RNA Amplification System
from Invitrogen Life Technologies (Superscript). Several
steps for synthesizing labeled target are identical for each
kit. For example, each kit uses reverse transcriptase with
an anchored oligo(dT) primer containing a T7 promoter
to synthesize first-strand cDNA. Then, following second
strand synthesis, the cDNA templates are amplified via the
Eberwine isothermal protocol [1]. Some of the differences
include the biotinylated nucleotides in the in vitro tran-
scription (IVT) reaction. The BioArray kit uses two bioti-
nylated nucleotides; One-Cycle, a biotinylated pseudo-
nucleotide and the Superscript kit a single biotinylated
nucleotide. Differences are also noted in the second
strand cDNA synthesis. The One-Cycle and Superscript
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kits use nick translation, whereas the BioArray kit uses a
homopolymeric tailing and an extension reaction. In our
study peripheral blood mononuclear cell (PBMC) RNA
from 2 donors was used in each of the three labeling kits.
Several parameters of these one-cycle labeling kits were
compared to determine factors that could affect gene
expression results.
Results
Each kit was used to label 2.5 μg total RNA extracted from
PBMC from two donors (A and B). The labeling reactions
were repeated for Donor A, resulting in 3 GeneChip arrays
for each kit.
The length of the synthesized cRNA targets was estimated
by overlaying the Bioanalyzer profiles onto the standard
size markers (Figure 1). Determinations were made at a y-
axis (fluorescence) value of 2 (twice the background
level). The sizes ranged from 100 to 5000 nucleotides for
the One-Cycle kit; 200 to 4000 nucleotides for the Super-
script kit, and 200 to 2000 nucleotides for BioArray kit
(Figure 1). On correction for different loading volumes
similar results were obtained. The cRNA yields were quite
different. The Superscript kit synthesized the highest
labeled amounts and the BioArray kit the lowest (Table 1).
Importantly, the BioArray methodology needed to be
repeated several times in order to obtain the required
yield from the IVT reaction. Approximately 50% of these
reactions failed to give an appropriate yield (data not
shown) and we do not believe this was user error.
The fragmentation of the cRNA target to 35 to 200 bases
is important for hybridization efficiency and assay sensi-
tivity [2]. The fragmentation protocol recommended by
Affymetrix was used in all cases. Approximately 160 ng of
the fragmented target (estimated from concentration of
starting material) was assessed using the Agilent 2100 Bio-
analyzer to determine population size relative to known
markers (Figure 2). The One-Cycle and Superscript kits
produced cRNA fragments with an average size of around
100 bases. The BioArray kit produced a slightly larger aver-
age size fragment of 125 bases. Even though the starting
concentration for each fragmentation reaction was the
same, the One-Cycle kit routinely gave almost double the
yield of fragmented cRNA than either the BioArray or
Superscript kits (Table 1).
Hybridization performance with standard array quality 
metrics
To verify the efficiency of the hybridization step we exam-
ined the results of the hybridization spike-in controls pro-
vided for the Affymetrix GeneChip (QC1). These controls
are a mixture of biotin-labeled cRNA transcripts of bioB,
bioC, bioD, and cre, prepared in staggered concentrations
(1.5 pM, 5 pM, 25 pM, and 100 pM respectively). These
are added into the hybridization cocktail, independent of
RNA sample preparation, and are used to evaluate hybrid-
ization efficiency. Not surprisingly the hybridization per-
formed equally well for the 3 kits as all control targets
were called present in all arrays and there was a linear
increase in signal with increasing concentrations of each
control cRNA transcript.
The background, RawQ and scaling factor quality metrics
were examined to determine if differences in labeling
affected the hybridization results. The average back-
ground values, derived from the intensity values of the
lowest 2% of cells on the chip, were within the recom-
mended 20–100 range for all 3 approaches. The Super-
script kit consistently gave higher readings with larger
variation (Table 1). The RawQ (or noise) value, derived
from the standard deviation of the background intensity
measurement was below 4 for each kit, as recommended
by Affymetrix. The scaling factor is inversely related to the
overall brightness of the chip and provides a measure of
the overall expression level of the array and was again,
comparable for all 3 labeling approaches (Table 1).
The percent present/absent calls were used to globally
assess the sensitivity of each labeling kit. The majority of
genes were consistently classified in the same category for
each labeling pair (88.6% for One-Cycle, 88.2% for Bio-
Array and 84.6% for Superscript). There was 74.2% call
agreement across the 3 methods (40,548 out of 54,675
probesets on the U133Plus2.0 GeneChip). Interestingly,
even though One-Cycle kit had the higher percent present
calls of all the kits, all had similar average signal intensi-
ties (Table 1). Signal intensities for the probe sets are com-
parable, but the Superscript kit has the highest variation
(Figure 3). A comparison of coefficients of variation on
normalized signal intensities shows an average 11% CV
for the One-Cycle kit compared to 12.1% and 12.3% for
BioArray and Superscript kits respectively (Table 1). When
we examine the correlation of differential fold change cal-
culations (between Donor A and Donor B) using all
54675 probesets across the labeling kits we find a 60.2%
agreement between the One-Cycle and BioArray kits,
(number of probesets present in quadrants B and D (Fig-
ure 4) compared to the total number of probesets). A
53.9% concordance is seen between the One-Cycle and
Superscript kits and 63% between the BioArray and Super-
script kits. This same analysis applied to data filtered for
present calls across all 6 arrays (11881 probesets, Figure 4)
showed an increase in concordance between the One-
Cycle and BioArray kits (65.7%) with a linear regression
fit of R2 = 0.43. For the two other combinations the per-
centage decreased to 51% for the One-Cycle/Superscript
combination (R2 = 0.02) and remained the same for the
BioArray/Superscript comparison (R2 = 0.3).BMC Biotechnology 2007, 7:24 http://www.biomedcentral.com/1472-6750/7/24
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Table 2 shows the averaged 3'/5' ratios for the internal
control genes, QC2, and gives the total distance covered
by the probesets for each. GAPDH and β-actin have the
shortest transcript lengths and Affymetrix suggests that
ratios < 3 are acceptable, as data quality is not significantly
affected when the ratios fall within these bounds [3]. All 3
methodologies met these criteria. There are probesets
directed to the 28S and 18S ribosomal RNA (rRNA) genes,
as these are not mRNAs they can be considered as negative
controls. Figure 5 shows a bar chart of the averaged signal
intensities for all the internal control gene probesets,
QC2. Signal intensities for the rRNA probesets from One-
Cycle are lower than either BioArray or Superscript. How-
ever, all probesets (3', middle and 5') were called as
present, except the 3' 28S rRNA which was absent on all 9
chips. ISGF-3 (Interferon-simulated gene factor 3) mRNA
is the longest transcript for the internal control genes and
has ratios = 3 for the One-Cycle and BioArray methodolo-
gies, and 1.5 for the Superscript kit.
Reproducibility of gene expression signal intensities
A compilation of the MA plots comparing the magnitudes
of change (log fold change) to the mean log expression
level for the same sample labeled by each kit is given in
Figure 6.
Intra- and inter-assay comparisons were determined using
the overall signal correlation. Pair-wise Pearson correla-
tion coefficients of the raw signal intensities were calcu-
lated using all transcripts. The intra-method
reproducibility for replicate samples had correlation coef-
ficients >0.99 for One-Cycle and BioArray kits and 0.98
for the Superscript kit. The One-Cycle and BioArray meth-
ods had the highest inter-method correlation coefficient
(averaged r = 0.972) whereas the Superscript kit was less
correlated (average r = 0.968 against One-Cycle and Bio-
Array). The inter-assay correlation range was 0.943 –
0.986. When we examine the non-parametric Spearman
Rank correlation coefficients generated for the normalized
probesets within the replicate samples One-Cycle has the
highest correlation (r = 0.936), followed by BioArray (r =
0.911) and then Superscript (r = 0.906). As the Spearman
correlation ranks the probesets by their intensity values,
this reflects the reproducibility of the labeling technolo-
gies.
Linearity and sensitivity of kits as quantified using spike-in 
bacterial poly-A control targets
The ability of any amplification and labeling method to
accurately detect differences in expression levels is highly
dependent on linearity, dynamic range of amplification
and sensitivity. We evaluated these parameters by analyz-
ing the spike-in poly-A control transcripts (QC3) added to
each total RNA sample at staggered concentrations. They
act as a convenient way to monitor the entire labeling
process, independent of the quality of the starting mate-
rial. All 4 spike-in controls were called Present in all
instances, indicating similar sensitivities. The averaged
signal intensities for the poly-A controls were plotted (Fig-
ure 7) for each of the probesets, (3', middle and 5'). Each
followed the same order of increasing poly-A control RNA
concentration as expected.
Discussion
Total RNA is ideal for gene expression profiling from clin-
ical specimens, small amounts can be used because the
methodology preserves the relative abundance of the dif-
ferent mRNAs in the original sample [4]. In evaluating a
new protocol or comparing existing protocols, measures
such as the yield of cRNA or the fraction of probe sets
detected can be useful, but the key measure is the extent to
which differences (or in this analysis similarities) in gene
expression can be detected. Several studies have compared
linear amplification protocols, similar to those used here,
with PCR-based techniques [5,6], or one-cycle labeling
kits to those that use two or three cycles for sample of 100
ng or less total RNA [7]. Ma et al. (2006) [8] compared IVT
labeling reactions from purified double-stranded cDNA
using the GE Healthcare CodeLink Expression System and
the 3'-amplification reagents from Affymetrix, showing
similar results to those obtained here. However, a litera-
Overlaid electropherograms from the analysis of unfrag- mented biotinylated cRNA products from the IVT reactions  of the 3 different labeling kits by the Agilent 2100 Bioanalyzer Figure 1
Overlaid electropherograms from the analysis of unfrag-
mented biotinylated cRNA products from the IVT reactions 
of the 3 different labeling kits by the Agilent 2100 Bioana-
lyzer. The replicate reactions from donor A are shown for 
each kit: One-Cycle data represented as blue and green line; 
BioArray as black and orange and Superscript by the pink and 
turquoise lines. 1 μl of the final volume (One-Cycle = 21 μl; 
BioArray = 60 μl; Superscript = 100 μl) of purified IVT reac-
tion is loaded. The RNA ladder (peaks represented in red) 
contains a mixture of RNAs of known concentration and size 
(50 (lower marker) 200, 500, 1,000, 2,000, 4,000, and 6,000 
bases from left to right).BMC Biotechnology 2007, 7:24 http://www.biomedcentral.com/1472-6750/7/24
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ture search revealed no publications comparing one-cycle
labeling kits directly. To examine the differences intro-
duced by different labeling kits, we compared 3 one-cycle
labeling kits commonly used with the Affymetrix Gene-
Chip platform. Each labeling method showed a high
degree of intra-method correlations in replicate experi-
ments, but lower inter-method correlation. Exploring the
fold changes between Donor A and Donor B across kits
(Figure 4) and the MA plots (Figure 5) showed the One-
Cycle and BioArray kits, gave the best correlation. The
poorest concordance was evidenced between the two
Eberwine-based protocols, One-Cycle and Superscript.
The use of the oligo(dT) primer in the first strand synthe-
sis in all the kits is to selectively amplify polyadenylated
transcripts. Therefore the ribosomal RNA probesets (to
18S and 28S rRNA) act as a negative control. As expected
for these probesets, the One-Cycle kit gave a signal just
above background, however, for both the BioArray and
Superscript kits a strong positive signal was detected for
the 18S rRNA probesets (Figure 7). This is of concern, as
any signal detected comes from either cross-hybridization
or non-specific priming. We believe these results can be
explained by the rapid cooling of the primer annealing
reaction in the One-Cycle methodology which reduces
some of the non-specific binding that may arise with the
slower cooling used in the Superscript or BioArray proto-
cols.
β-actin and GAPDH internal control probesets are com-
monly used to assess RNA sample and assay quality
[3,9,10]. The other probesets classified as internal con-
trols are rarely referred to in the literature, probably
because the two rRNA probesets (discussed above), are
known to have very high coefficients of variation [11] and
the ISGF3 probesets cover 2639 nucleotides of the mRNA,
a particularly long transcript for Affymetrix GeneChips.
Other possible causes for the differences in results
between the labeling kits are the use of different reverse
transcriptase enzymes, T7oligo dT primers (which could
differ in promoter sequence and length of poly-T tail) and
concentration of nucleotides. BioArray uses a very differ-
ent strategy to generate the second strand in the cDNA
synthesis – a homopolymeric tail to the cDNA, followed
by an extension reaction. The other kits use a nick-transla-
tion reaction. The IVT reaction for amplification and labe-
ling of the target is similar in most aspects, except the
BioArray method uses two nucleotide labels (biotin-CTP
and biotin-UTP), the Superscript kit a single biotin-UTP
labeling and the One-Cycle, a ψ-UTP biotinylated nucleo-
tide (Table 3). Samples labeled by the BioArray method
had higher, unnormalized fluorescence intensity values
than the other methods (Table 1), possibly due to incor-
poration of the two labeled nucleotides. The higher
number of present calls on the One-Cycle kit array indi-
cates a higher labeling efficiency, but this did not appear
Table 1: Comparison of different measures for each of the 3 kits assessed in this study.
Stage Parameters One Cycle Rank BioArray Rank Superscript Rank
Labeling Protocol cRNA yield (ug)* 54.6 ± 0.6 2 43.1 ± 2.4 3 86.3 ± 10.9 1
Reproducibility 1 2 3
Peak range cDNA product sizes (bases) 100 – 2000 1 800 3 750–2000 2
Average fragment length (bases) 100 1 125 1 100 1
Fragmentation cRNA yield (ug)* 9.2 ± 4.3 1 4.6 ± 1.2 2 4.5 ± 1.3 2
Total time labeling reaction 22.5 1 23.5 3 22.75 2
Number of steps to labeling reaction 7 1 11 2 6 1
Cost per labeling reaction $115.00 3 $106.00 2 $95.00 1
Signal measures % of Present* 38.6 ± 0.7 1 36.8 ± 5.4 2 34.7 ± 6.4 3
Scaling Factor* 16.6 ± 7.7 3 13.7 ± 1.9 1 14.0 ± 1.4 2
Median array raw intensity* 143.1 ± 8.7 2 131.6 ± 33.6 3 168.6 ± 47.0 1
Mean array raw intensity* 1042.6 ± 34.3 3 1160.7 ± 127.5 1 1104.6 ± 73.5 2
Background* 37.4 ± 3.8 1 41.8 ± 8.6 2 49.9 ± 21.9 3
Raw Q (Noise)* 1.23 ± 0.2 1 1.4 ± 0.5 2 1.7 ± 0.8 3
Number Present (P) 21099 ± 389 1 20119 ± 2962 2 18953 ± 3477 3
Number Absent (A) 32744 ± 360 3372 ± 2933 34846 ± 3461
Number Marginal (M) 832 ± 81 1 834 ± 13 2 877 ± 16 3
Average Signal (P) 2550.4 ± 125.4 3 3054.3 ± 660.8 2 3074.7 ± 451.1 1
Average Signal (A) 90.5 ± 12.5 88.8 ± 35.3 143.9 ± 42.7
Average Signal (M) 295.5 ± 36.0 279.5 ± 105.9 430.3 ± 121.6
Average CV on GC-RMA normalized signal (All 
3)
15.7% 18.0% 16.0%
Average CV on GC-RMA normalized signal 
(Replicates only)
11.0% 1 12.1% 2 12.3% 3
Internal Control genes β- a c t i n / G A P D H  r a t i o s 111
rRNA signal 1 3 2
Total score 30 41 40
Several criteria were evaluated for each stage in the generation of labeled target and each afforded a score relative to performance 1 = good, 3 = worst.BMC Biotechnology 2007, 7:24 http://www.biomedcentral.com/1472-6750/7/24
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to be because of greater label incorporation, as signal
intensities were no higher in the One-Cycle kit arrays
compared to the other two.
The methodological differences elucidated above, will
each make a contribution towards the differences in cRNA
profiles that were noted when an aliquot of each was run
on the Bioanalyzer (Figure 1). These differences were not
a result of loading different quantities of cRNA on the Bio-
analyzer chips, as similar results were obtained when
equivalent amounts of cRNA were run. The differences
included length of product, yield and reproducibility of
the methodology. A cRNA profile with a greater propor-
tion of fragments above 500 nt is usually considered as a
good preparation, therefore despite the differences, each
of the kits provides target cRNA that passes the suggested
parameters established by Affymetrix and our results sup-
port this. Once the biotinylated target cRNA has been syn-
thesized, it is then fragmented by metal-induced
hydrolysis. Considering that a set amount of cRNA goes
into each reaction (20 μg) and the same protocol was used
for all the fragmentations, we were surprised to note the
differences in the fragmentation profiles for each kit. The
BioArray and Superscript protocols give far smaller yields
when compared to the One-Cycle kit cRNA. The 3 kits
each use spin-cartridges with differing reagents to clean-
up the cRNA, and the product is eluted in RNAse-free
water in each case. The BioArray and Superscript kits
require that the target be concentrated in a vacuum con-
centrator for fragmentation. We cannot be sure what the
carry-over (i.e. ion concentration) is from these steps, and
it is possible that this could affect the fragmentation reac-
tion, possibly causing complete hydrolysis and loss of
product.
Probably the largest draw back that we experienced with
any of the kits was the number of times that the BioArray
kit failed to produce sufficient product for fragmentation
(50% of reactions). This is probably due to losses incurred
from the two additional purification steps (after the
reverse transcription and again after the homopolymeric
tailing) in this methodology. This is not an acceptable sit-
uation when processing limited clinical samples. Enzo
Life Sciences has recently released a new labeling kit based
on the Eberwine protocol, which they currently recom-
mend for use with Affymetrix GeneChips. Other consider-
ations we used in evaluating the kits were ease of use,
measured by the number of steps involved in the protocol
and cost of each labeling reaction (Table 2).
Conclusion
The results of this study show that different one cycle labe-
ling kits from different manufacturers generate products
that vary in size distribution and yield. The One-Cycle Tar-
get Labeling Assay from Affymetrix and the Superscript™
RNA Amplification System from Invitrogen Life Technol-
ogies each use the nick translation methodology for gen-
eration of second-strand cDNA and were the most similar
in terms of product generated. Whereas the BioArray™
RNA Amplification and Labeling System from Enzo Life
Sciences uses an extension reaction after homopolymeric
tails are added, and this kit produces a quite different
product profile. The results of hybridizing each of the
labeling kit products to Affymetrix GeneChip arrays
showed much less variation in terms of gene expression
results than expected from the product profiles. The One-
Cycle and BioArray kits produced the most concordant
data. Since the results generated from the different labe-
ling kits are fairly comparable, factors such as kit cost,
time and difficulty should be considered when selecting a
one-cycle labeling approach for use with Affymetrix Gene-
Chips. These results emphasize that data generated from
different labeling methodologies cannot be directly com-
pared.
Overlaid Bioanalyzer electropherograms for fragmented  labeled cRNA targets showing the size distribution of frag- mented target Figure 2
Overlaid Bioanalyzer electropherograms for fragmented 
labeled cRNA targets showing the size distribution of frag-
mented target. One-Cycle replicates (blue and green); Super-
script replicates (orange and black); BioArray replicates (pink 
and turquoise). RNA ladder in red showing the lower align-
ment marker and the 200 and 500 base markers.BMC Biotechnology 2007, 7:24 http://www.biomedcentral.com/1472-6750/7/24
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Methods
Sample processing
Peripheral blood mononuclear cells were used as the
source of total RNA for these experiments. Blood was
drawn from two donors (Donor A and B) into 8 ml Vacu-
tainer Cell Preparation Tubes with sodium citrate (BD,
NJ), and immediately processed according to manufac-
turer's instructions. Total RNA was isolated using TRIzol™
Reagent (Invitrogen, CA). Integrity and concentration of
the RNA were evaluated using the Agilent Bioanalyzer
2100 capillary electrophoresis RNA 6000 Nano Kit (Agi-
lent Technologies, CA). RNA with a 28S:18S RNA ratio
greater than 1.8 was used in this study.
Target preparation
Three commercially available target labeling kits compat-
ible with the Affymetrix GeneChip platform were assessed
in this study. These were: One-Cycle Target Labeling Assay
from Affymetrix ((One-Cycle), Santa Clara, CA) [2],
which includes the sample clean-up modules; BioArray™
RNA Amplification and Labeling System (with biotin-
labeled ribonucleotide mix) from Enzo Life Sciences
((BioArray), Farmingdale, NY) [12] used along with the
RNeasy Mini and MinElute Kits (Qiagen, Valencia, CA)
for purification of reaction products; and Superscript™
RNA Amplification System from Invitrogen Life Technol-
ogies ((Superscript), Carlsbad, CA) [13] incorporating the
modifications for GeneChip applications as suggested in
the manual using biotin-11-UTP purchased from Perkin-
Elmer (Boston, MA).
Each labeling reaction used 2.5 μg total RNA and was
completed by the same researcher to minimize user-asso-
ciated variability. Three reactions were performed per kit:
two using Donor A to assess technical variation, and a
third using RNA from Donor B. The Eukaryotic Poly-A
RNA Control Kit designed by Affymetrix to provide exog-
enous positive controls to monitor the entire target labe-
ling process (QC3) were used with each of the 3 kits. Poly-
A RNA controls were processed as directed for 5 μg total
RNA immediately before performing the experiment. This
doubled the final concentration of the spike-in controls to
the total RNA. The methods compared, are summarized in
Table 3. The cRNA amplification products from the IVT
reaction (1 ul from final purification volume) were exam-
ined on the Agilent Bioanalyzer to obtain the size distri-
bution and yield.
Fragmentation and hybridization of labeled target
Twenty μg of purified cRNA was incubated in Affymetrix
fragmentation buffer at 94°C for 35 minutes and 150 ng
of fragmented target was assessed using the RNA 6000
Nano Kit, Agilent 2100 Bioanalyzer. Hybridization buffer,
the Eukaryotic Hybridization Controls (used to confirm
the sensitivity of hybridization, QC1), and the OligoB2
controls (positive controls used to orient and grid the
array), were added to the fragmented cRNAs. Labeled tar-
gets were hybridized on Affymetrix Human U133 plus 2.0
chips at 45°C for 16 hours as described in the Affymetrix
Users manual [2]. Washing and staining of arrays were
performed using the GeneChip Fluidics Station with the
EukGE-WS2v5_450 protocol. Chips were scanned using
the Affymetrix GeneChip Scanner 3000.
Correlation of fold-change calculations across different labe- ling kits Figure 4
Correlation of fold-change calculations across different labe-
ling kits. Fold-changes were calculated for probesets called 
present (11881 probesets) in all samples between Donor A 
and Donor B for each labeling kit. Quadrants B and D repre-
sent data points that are concordant with respect to direc-
tion of fold change. Quadrants A and C represent discordant 
fold change results. Left: One-cycle vs. BioArray. Center: 
One-Cycle vs. Superscript. Right: BioArray vs. Superscript.
Box plots of logged probe level signal intensities for each of  the GeneChip arrays included in this study Figure 3
Box plots of logged probe level signal intensities for each of 
the GeneChip arrays included in this study.BMC Biotechnology 2007, 7:24 http://www.biomedcentral.com/1472-6750/7/24
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Analysis of gene expression data
Image acquisition, quantification and data analysis were
performed using the Affymetrix GeneChip Operating Soft-
ware (GCOS) v1.4.0.036. Each sample was scaled to a tar-
get intensity of 500 for all probe sets. This option scales
the trimmed mean intensity to the specified value. The
expression report generated using the GCOS software was
used to examine raw signal values and detection calls
(present (P), absent (A), marginal (M). Data was normal-
ized using the MAS5 algorithm.
All gene expression data has been deposited in the
ArrayExpress repository [14] under the accession number
E-MEXP-884, and is available to the public.
Bar chart showing averaged signal intensities for all internal control probesets (QC2) with corresponding standard deviations Figure 5
Bar chart showing averaged signal intensities for all internal control probesets (QC2) with corresponding standard deviations.
Table 2: 3'/5' ratios of Housekeeping genes (internal control genes, QC2) given as average ± standard deviation.
Internal Control Genes 3'/5' Signal Ratios (Average ± SD)
Probe ID Gene Length Transcript (bases) Affy Enzo Invitro
AFFX-HUMGAPDH/M33197 GAPDH 1169 1.5 ± 0.2 1.1 ± 0.2 1.5 ± 0.3
AFFX-HSAC07/X00351 beta-Actin 1688 1.6 ± 0.2 1.5 ± 0.2 1.2 ± 0.1
AFFX-HUMRGE/M10098 18S rRNA 1795 0.9 ± 0.2 1.0 ± 0.2 0.8 ± 0.1
AFFX-M27830 28S rRNA 1816 0.03 ± 0.01* 0.02* 0*
AFFX-HUMISGF3A/M97935 ISGF3 2639 4.2 ± 1.8 3.0 ± 0.3 1.5 ± 0.1
* 3' signal called absentBMC Biotechnology 2007, 7:24 http://www.biomedcentral.com/1472-6750/7/24
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MA plots comparing the magnitude of change (log(signal array1) - log(signal array2)) on the y axis against the average log signal  intensity (x axis) Figure 6
MA plots comparing the magnitude of change (log(signal array1) - log(signal array2)) on the y axis against the average log signal 
intensity (x axis). The green threshold lines show ± 2-fold changes. The color coding of the plot indicates the density of 
probesrepresented by that data point. The kits compared in each plot are given on the right hand side and the donor sample 
labeled by the kit is indicated at the top of each plot.BMC Biotechnology 2007, 7:24 http://www.biomedcentral.com/1472-6750/7/24
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Abbreviations
cDNA complementary deoxyribonucleic acid
IVT in vitro transcription
cRNA complementary ribonucleic acid
ng nanogram
mRNA messenger ribonucleic acid




aRNA amplified ribonucleic acid
GCOS GeneChip Operating Software
PBMC peripheral blood mononuclear cells
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Evaluation of transcripts spiked into the total RNA sample (poly-A controls, QC3) Figure 7
Evaluation of transcripts spiked into the total RNA sample (poly-A controls, QC3). Averaged signal intensity of each of the 3 
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Table 3: Comparison of labeling methodologies for kits compared in this study.






Optimized Total RNA (μg) 1 to 15 1 to 10 1 to 5
First Strand Synthesis Total RNA used 2.5 μg1 . 52 . 5   μg 1.25 2.5 μg2 . 5
Primer T7-oligo(dT) T7-oligo(dT) T7-oligo(dT)
Primer annealing/RNA 
denaturation
70°C × 10' and 4°C × 2' 70°C × 10' 70°C × 10'
Reverse transcriptase Superscript II Proprietary Superscript III
Final reaction volume 20 μl 20 μl2 0   μl
Incubation conditions 42°C × 1 h 42°C × 1 h 46°C × 2 h
Inactivate RT - - 70°C × 10'
RNA elimination - Base hydrolysis/
Neutralization
0.5 -
Purification - Spin cartridge 1 0.5 -
Tailing and 
Termination
Methodology - Homopolymeric tail added 1 -
Purification - Spin cartridge 1 0.5 -
Second Strand cDNA 
synthesis
Methodology Nick translation reaction 2.5 Extension reaction 1.25 Nick translation 
reaction
2
Volume used from previous 
reaction
All All All
Final reaction volume 150 μl 30 μl 150 μl in 2 tubes
Incubation conditions 16°C × 2 h 42°C × 1 h 16°C × 2 h
T4 DNA polymerase (sticky 
ends)
16°C × 5' - -
Stop reaction EDTA addition - -
Purification Spin cartridge 0.5 Spin cartridge 1 0.5 Spin cartridge 0.25
In vitro transcription 
amplification
Volume used from previous 
reaction
All 16.25 All 16.25 All 16.5





Final volume IVT 42 μl 40 μl4 0   μl
Incubation conditions 37°C × 16 h 37°C × 16 h 37°C × 16 h
DNAse I digestion - - 37°C × 30'
Purification Spin cartridge 0.5 Spin cartridge 2 0.5 Spin cartridge 0.25
Volume after purification 21 μl 60 μl 100 μl
Methodology Affymetrix Affymetrix Affymetrix
Fragmentation 
protocol
Amplified RNA used 20 μg1 . 2 52 0   μg1 . 2 5 2 0   μg1 . 2 5
Final volume Fragmentation 40 μl 40 μl4 0   μl
Total Hours 22.5 23.5 22.75
Number of steps 7 11 6
All details are taken from manufacturers manuals supplied with each kit.Publish with BioMed Central    and   every 
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